Eywa Biotech
PrivateLast Round
Seed
Oct 3, 2025
Total Funding Raised
$2.6M
Momentum Score
50 /100
Company Overview
Eywa Biotech is a biotechnology company that develops clinical-grade psychedelic compounds for the treatment of mental health conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Pharma Supply Chain, Mental Health
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Eywa Biotech Comps
Public and private peers based on sector, stage, and business model.
Eywa Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Oct 3, 2025 |
Key People
Founding team and executive leadership
Eywa Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GRIDX | Seed |
| Draper Associates | Seed |
| Draper Cygnus | Seed |
| Agencia Nacional de Investigación e Innovación | Pre Seed |
| Panambi Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 1, 2026
Grew 44% QoQ from 9 to 13 employees.
- Apr 21, 2026
Grew 71% QoQ from 7 to 12 employees.
Eywa Biotech Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Eywa Biotech's valuation, stock price, and market status.
